Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors

PURPOSE: Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to molecular characteristics. Consensus treatment strategies for class 2 and 3 BRAF mutations h...

Descripción completa

Detalles Bibliográficos
Autores principales: Dankner, Matthew, Wang, Yifan, Fazelzad, Rouhi, Johnson, Benny, Nebhan, Caroline A., Dagogo-Jack, Ibiayi, Myall, Nathaniel J., Richtig, Georg, Bracht, Jillian W.P., Gerlinger, Marco, Shinozaki, Eiji, Yoshino, Takayuki, Kotani, Daisuke, Fangusaro, Jason R., Gautschi, Oliver, Mazieres, Julien, Sosman, Jeffrey A., Kopetz, Scott, Subbiah, Vivek, Davies, Michael A., Groover, Anna L., Sullivan, Ryan J., Flaherty, Keith T., Johnson, Douglas B., Benedetti, Andrea, Cescon, David W., Spreafico, Anna, Zogopoulos, George, Rose, April A.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530862/
https://www.ncbi.nlm.nih.gov/pubmed/35977349
http://dx.doi.org/10.1200/PO.22.00107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530862/
https://www.ncbi.nlm.nih.gov/pubmed/35977349
http://dx.doi.org/10.1200/PO.22.00107

Ejemplares similares